Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 18:1-16.
doi: 10.1007/s41060-022-00371-8. Online ahead of print.

Learning to discover medicines

Affiliations
Review

Learning to discover medicines

Minh-Tri Nguyen et al. Int J Data Sci Anal. .

Abstract

Discovering new medicines is the hallmark of the human endeavor to live a better and longer life. Yet the pace of discovery has slowed down as we need to venture into more wildly unexplored biomedical space to find one that matches today's high standard. Modern AI-enabled by powerful computing, large biomedical databases, and breakthroughs in deep learning offers a new hope to break this loop as AI is rapidly maturing, ready to make a huge impact in the area. In this paper, we review recent advances in AI methodologies that aim to crack this challenge. We organize the vast and rapidly growing literature on AI for drug discovery into three relatively stable sub-areas: (a) representation learning over molecular sequences and geometric graphs; (b) data-driven reasoning where we predict molecular properties and their binding, optimize existing compounds, generate de novo molecules, and plan the synthesis of target molecules; and (c) knowledge-based reasoning where we discuss the construction and reasoning over biomedical knowledge graphs. We will also identify open challenges and chart possible research directions for the years to come.

Keywords: Artificial intelligence; Biomedical representation learning; Drug discovery; Drug discovery reasoning; Machine learning.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestAll authors have no conflict of interest to report.

Figures

Fig. 1
Fig. 1
Three aspects of AI in drug discovery: (i) Transforming the biological data into representations readable by computer; (ii) data-driven reasoning in which models estimated from data are used to infer properties, optimize, generate molecules and plan synthesis; and (iii) reasoning with biomedical knowledge graphs

References

    1. Zhang, D., Mishra, S., Brynjolfsson, E., Etchemendy, J., Ganguli, D., Grosz, B.: et al. The AI Index 2021 Annual Report. (2021) arxiv: 2103.06312
    1. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R & D efficiency. Nat. Rev. Drug Discov. 2012;11(3):191–200. doi: 10.1038/nrd3681. - DOI - PubMed
    1. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem. Rev. 2019;119(18):10520–10594. doi: 10.1021/acs.chemrev.8b00728. - DOI - PubMed
    1. The Drug Development Process. https://wwwfdagov/patients/learn-about-drug-and-device-approvals/drug-development-process;
    1. Wang R, Fang X, Lu Y, Yang CY, Wang S. The PDBbind database: methodologies and updates. J. Med. Chem. 2005;48(12):4111–4119. doi: 10.1021/jm048957q. - DOI - PubMed

LinkOut - more resources